Independent symposium at the 10th World Congress on Controversies in Multiple Myeloma (COMy)
Chaired by Mohamad Mohty, and featuring Rakesh Popat, Suzanne Lentzsch and Saad Usmani, this CME-accredited symposium focussed on an overview of the multifaceted landscape of BCMA-targeting strategies in multiple myeloma, including anti-BCMA bispecific antibodies, anti-BCMA ADCs, and anti-BCMA CAR-T cells, offering insights into the latest clinical data and their implications for clinical practice. The session concluded with a comprehensive discussion addressing challenges and future needs in myeloma therapy.
Learning objectives
After viewing the webcast, you will be able to:
- Explain the different BCMA-targeting strategies for patients with MM
- Evaluate the latest clinical data available for these therapies and their implications for clinical practice
- Assess challenges and remaining needs for the future of myeloma therapy
Agenda
- Welcome and introduction
- Where do we stand with the different modalities of therapy?
- Anti-BMCA bispecific antibodies
- Anti-BCMA ADCs
- Anti-BCMA CAR-T cells
- Discussion and Q&A
- Close
Faculty
Mohamad Mohty
Sorbonne University, France
Dr Mohamad Mohty is a Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University in Paris, France. He obtained his medical degree from the University of Montpellier, France, and PhD from the University of Marseille, France. He is also head of a translational research team (Inserm) at the Saint-Antoine Research Centre in Paris.
Dr Mohty is the past president of the European Society for Blood and Marrow Transplantation (EBMT), and the current chairman of the Acute Leukemia Working Party of the EBMT. He is also the founder and chairman of the International Academy for Clinical Hematology (IACH) and board member of the EBMT and the Intergroupe Francophone du Myelome (IFM).
In addition to publishing more than 900 peer-reviewed articles in the field of stem cell transplantation, leukemia, and myeloma, Dr Mohty also serves as Editor-in-Chief of the journals Bone Marrow Transplantation and Clinical Hematology International.
Disclosures
Honoraria: Adaptive Biotechnologies, Amgen, Astellas, BMS, GSK, Janssen, Jazz, Novartis, Pfizer, Sanofi, Stemline, Takeda
Research funding: Janssen, Sanofi
Suzanne Lentzsch
Columbia University, USA
Dr. Lentzsch is a Professor of Medicine and the Director of Multiple Myeloma and Amyloidosis Service at Columbia University Medical Center, New York. Her translational research identifies novel targets for treating MM, MM bone disease, and AL amyloidosis. In a series of multicenter clinical trials, she established bendamustine as a new treatment for relapsed amyloidosis. In an FDA-funded, first-in-human phase 1 trial, she studied the monoclonal antibody 11-1F4 (Cael-101) that targets amyloid fibrils. Based on her work Caelum Biosciences was founded, and Cael-101 is currently being tested in a phase 3 trial.
Dr. Lentzsch is Co-Chair of the NCI Myeloma Steering Committee, a member of ASH Scientific Committee for Plasma Cell Neoplasia, the Educational and Steering Committee for the Society of Hematology and Oncology, and the SWOG Myeloma Working Group. She co-chairs the Career Development Committee of the International Myeloma Society. She is Associate Editor for JCO and on the Editorial Board for Blood Cancer Discoveries.
Disclosures
Dr. Lentzsch’s translational research received grant support from the NCI, FDA, Pennsylvania Department of Health, Leukemia and Lymphoma Society, Multiple Myeloma Research Foundation, Cancer Research Institute, Emerson Collect Fund, and International Myeloma Society. Dr. Lentzsch has published over 140 original articles, editorials, and chapters, many as lead or senior author, in high-impact journals such as JCI, JCO, Blood, Cancer Research, and Leukemia.
Saad Usmani
Memorial Sloan Kettering Cancer Center, USA
Dr. Usmani received his medical education at Allama Iqbal Medical College in Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut.
He joined the Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences in Little Rock, AR in 2010 as the Director of Developmental Therapeutics. He was recruited to the Levine Cancer Institute/Atrium Health in 2013 as the inaugural Division Chief of Plasma Cell Disorders and Director of Clinical Research for Hematologic Malignancies where he built an internationally renowned myeloma program. He joined Memorial Sloan Kettering Cancer Center in 2021 as the Chief of Myeloma Service and hold a faculty position as Professor of Clinical Medicine at Weill Cornell Medical College, Cornell University.
Dr. Usmani is board-certified in internal medicine, medical oncology, and hematology. He holds membership and leadership roles on national/international committees, including the International Myeloma Working Group, the ALLIANCE Myeloma Committee (Chair), the American Society of Hematology (ASH), the American Society of Clinical Oncology, International Myeloma Society (Board Member), the American Society of Transplant & Cellular Therapy, and the National Cancer Institute Myeloma Steering Committee. Dr. Usmani has served as the Vice-Chair of the SWOG Myeloma Committee, and has served as chair for the ASH Scientific Committee on Plasma Cell Neoplasia, and the ASCO Scientific Committee on Plasma Cell Disorders.
He has received several international awards recognizing his clinical and translational research contributions to the field, including the Celgene Young Investigator Award for Clinical Research, COMY Award for Excellence in Myeloma Research, LLS Scholar in Clinical Research, the International Myeloma Society Bart Barlogie Award for Clinical and Translational Research, and the LLS CDP Achievement Award. Dr. Usmani has authored/co-authored more than 270 peer-reviewed research manuscripts (NEJM, Lancet, JCO, Cancer Cell, Blood, Leukemia, etc.). Active in clinical and translational research, Dr. Usmani has research interests focus on plasma cell disorders—in particular, high-risk multiple myeloma.
Disclosures
Dr Usmani has received grant from Abbvie, Amgen, Array Biopharma, BMS, Celgene, Gilead, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda
Honoraria: Abbvie, Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio
Rakesh Popat
University College London Hospitals NHS Foundation Trust, London, UK
Dr Rakesh Popat is an Associate Professor at University College London and Consultant Haematologist at University College London Hospitals with an interest in multiple myeloma.
He graduated from Guy’s and St. Thomas’ Medical School in London and trained in haematology at St. Bartholomew’s and the Royal London Hospitals. During this time he completed a PhD in novel treatments for myeloma and was awarded a fellowship to attend the Dana Farber Cancer Institute, Boston USA as part of this.
He has particular experience with novel treatments including immunotherapies such as CAR-T cell therapy and new antibody approaches. At University College Hospital, he leads the myeloma clinical trials programme, is the Cancer lead at the NIHR UCLH Clinical Research Facility and trials co-lead for the UCL Experimental Cancer Medicine Centre.
Dr Popat is the Chair of the UK Myeloma Research Alliance, NCRI Myeloma working group, is on the executive board of the UK Myeloma Society, the Young Board of the European Myeloma Network and a member of the International Myeloma Working Group. He is the Chief Investigator for a number of relapsed myeloma studies and the Principal Investigator for the NIHR Health Informatics Collaborative Myeloma database.
Disclosures
Research Support/P.I.: GSK
Consultant: GKS
Honoraria: Janssen, Abbvie, GSK, BMS, Pfizer, Sanofi
Scientific Advisory Board: Janssen, Abbvie, Roche
Travel/Meeting Attendance Support: Janssen
Audience
This program is targeted at Hematologists, oncologists, oncology nurses, and all other HCPs managing MM.
Educational grant
Independent symposium organized by Springer Healthcare IME. This program is made possible thanks to an educational grant received from GlaxoSmithKline.
